Hillhurst Biopharmaceuticals, Inc.
Glendale, CA
- UEI
- G5YJYCGDUZD7
- CAGE
- 6ZWL9
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 2029 N Verdugo Rd, Glendale, CA 91208, USA
- Website
- hillhurstbio.com
- Founded
- 2012
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
Hillhurst Biopharmaceuticals, Inc., doing business as Hillhurst Biopharmaceuticals Inc., is a biopharmaceutical company focused on developing innovative therapies based on novel formulations of low-dose gases. The company specializes in creating oral formulations of carbon monoxide and nitrous oxide for various medical applications. Hillhurst has been registered to receive federal awards since October 11, 2013, and has a history of securing research grants from multiple institutes within the National Institutes of Health (NIH). These grants support the company's efforts to develop and evaluate new drug candidates for a range of diseases and conditions, including cystic fibrosis, sickle cell disease, viral-induced lung injury, Parkinson's disease, diabetic retinopathy, anthracycline-related cardiotoxicity, and ulcerative colitis.
The company's federal grant awards primarily support research and development activities for its lead candidates, HBI-002 and HBI-201. HBI-002, an oral formulation of low-dose carbon monoxide, is being investigated for multiple indications, including cystic fibrosis (funded by the National Heart, Lung, and Blood Institute), virus-induced lung injury (funded by the National Institute of Allergy and Infectious Diseases), Parkinson's disease (funded by the National Institute of Neurological Disorders and Stroke), diabetic retinopathy (funded by the National Eye Institute), and ulcerative colitis (funded by the National Institute of Diabetes and Digestive and Kidney Diseases). HBI-201, an oral formulation of nitrous oxide, is being developed for the treatment of pain associated with vaso-occlusive crises in sickle cell disease, supported by a cooperative agreement with the National Institute of Neurological Disorders and Stroke. These projects typically involve preclinical studies in animal models, mechanism of action investigations, and preparation for clinical trials. The grants cover various research activities, including efficacy studies, safety assessments, pharmacokinetic analyses, and the advancement of novel therapeutic approaches for unmet medical needs.
Quick answers
Is Hillhurst Biopharmaceuticals, Inc. registered in SAM.gov?
Yes. Hillhurst Biopharmaceuticals, Inc.'s SAM.gov registration is active through September 18, 2027.
What is Hillhurst Biopharmaceuticals, Inc.'s most recent federal award?
Hillhurst Biopharmaceuticals, Inc.'s most recent federal grant award is HBI-002 for cystic fibrosis (R41HL167404), from National Heart Lung and Blood Institute (NIH), on April 15, 2024.
On GovTribe
See Hillhurst Biopharmaceuticals, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors